Investors: Press Releases

  • All
  • Non-Regulatory
  • Regulatory
Regulatory

Allarity Therapeutics A/S Publishes Offer Document Offering to Acquire Company Shares in Exchange for Shares in Allarity Therapeutics, Inc. with the Intent to Complete Recapitalization

Regulatory

Grant of New Warrants and Resolutions on Existing Warrants

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – September 2021

Regulatory

Minutes of Extraordinary General Meeting held on 22 November 2021

Regulatory

Allarity Therapeutics’ Oral PARP Inhibitor, Stenoparib, Demonstrates Pre-clinical Antiviral Activity Against Delta Variant of Coronavirus

Regulatory

NOTICE OF THE EXTRAORDINARY GENERAL MEETING OF SHAREHOLDERS OF ALLARITY THERAPEUTICS A/S TO BE HELD ON NOVEMBER 22, 2021

Regulatory

U.S. SEC Issues Order Declaring Allarity Therapeutics Inc.’s Form S-4 Registration Statement Effective Ahead of Planned Transition to U.S. Nasdaq

Regulatory

Allarity Therapeutics and Lonza Collaborate to Manufacture Dovitinib, a Renal Cell Carcinoma Candidate

Regulatory

Allarity Therapeutics Presents Dovitinib Survival Data from DRP® Screened RCC Patients at ESMO 2021 Virtual Congress

Regulatory

Update: Allarity Therapeutics Receives Approximately SEK 23.3 Million (US $2.7 Million) from Subscription to Warrants of Series ALLR TO 2 and TO 3

Regulatory

Allarity Therapeutics Receives Approximately SEK 16.5 Million (US $1.9 Million) from Subscription to Warrants of Series ALLR TO 3

Regulatory

MINUTES OF EXTRAORDINARY GENERAL MEETING 2021

Regulatory

Allarity Therapeutics Announces Extraordinary Exercise Period for Warrants of Series ALLR TO 3 Set to August 30 – September 13, 2021

Regulatory

Allarity Therapeutics Files Form S-4 Registration Statement with U.S. Securities & Exchange Commission (SEC) for Listing on U.S. Nasdaq

Regulatory

Allarity Therapeutics Publishes Interim Report for the Period January – June 2021

Regulatory

New Publication Date for Allarity Therapeutics’ Q2 2021 Interim Report

Regulatory

Allarity Therapeutics Elaborates on the Contents of the Meeting Agenda for the Extraordinary General Meeting Announced on August 16, 2021

Regulatory

NOTICE OF EXTRAORDINARY GENERAL MEETING

Regulatory

Allarity Therapeutics’ oral PARP inhibitor, Stenoparib, demonstrates additional pre-clinical antiviral activity against new variants of Coronavirus

Regulatory

Allarity Therapeutics and Lantern Pharma Enter into Agreement for Future Clinical Development of Irofulven

Sign up for press releases

Sign up for press releases and receive relevant information about Allarity Therapeutics A/S.